INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

This study is testing whether using inhaled insulin (Afrezza) as part of a treatment regimen in the first days after a Type 1 diabetes diagnosis can help preserve the body's remaining insulin-producing cells and improve blood sugar control. It is specifically for children and teenagers who have just been diagnosed with Type 1 diabetes. **You may be eligible if...** - You are between 10 and 17 years old - You have been newly diagnosed with Type 1 diabetes (stage 3, meaning you have symptoms and elevated blood sugar) - Treatment can begin within 10 days of your first insulin injection (or within 10 days of being discharged if you were hospitalized) - Your lung function is normal or near normal (FEV1 above 80% of expected) **You may NOT be eligible if...** - You previously received insulin treatment for stage 2 (pre-symptomatic) Type 1 diabetes - You have a chronic lung condition such as asthma, COPD, cystic fibrosis, or any other serious lung disease - You are allergic to human regular insulin - You are currently smoking Talk to your doctor to see if this trial is right for you.